HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on ATAI Life Sciences (NASDAQ:ATAI) and maintained a price target of $15.
July 31, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on ATAI Life Sciences and maintained a price target of $15.
The reiteration of a Buy rating and a maintained price target of $15 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100